B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis

Arthritis Research and Therapy

Volumn 15, Issue 5, 2013, Pages

  François, Antoine ^a   Chatelus, Emmanuel ^b   Wachsmann, Dominique ^a   Sibilia, Jean ^a,b   Bahram, Seiamak ^a   Alsaleh, Ghada ^a   Gottenberg, Jacques Eric ^a,b  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; B CELL ACTIVATING FACTOR; B CELL MATURATION ANTIGEN; COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 1 A1; COLLAGEN TYPE 1 A2; COLLAGEN TYPE 3; COLLAGEN TYPE 3 A1; GELATINASE B; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; METHOTREXATE; MONOCYTE CHEMOTACTIC PROTEIN 1; PREDNISONE ACETATE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; ACTIN; ANTI-IGM; ANTIIDIOTYPIC ANTIBODY; IMMUNOGLOBULIN M; MMP9 PROTEIN, HUMAN; TIMP1 PROTEIN, HUMAN; TNFSF13B PROTEIN, HUMAN;

ARTICLE; B LYMPHOCYTE; BLOOD DONOR; BONE MARROW CELL; CELL ASSAY; CELL CONTACT; CELL CULTURE; CLINICAL ARTICLE; COCULTURE; COLLAGEN SYNTHESIS; CONTACT INHIBITION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; MYOFIBROBLAST; PRIMARY CULTURE; PROCEDURES; PROTEIN EXPRESSION; PROTEIN SECRETION; PUNCH BIOPSY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN BIOPSY; SKIN FIBROBLAST; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; UPREGULATION; CHEMISTRY; CYTOLOGY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; FIBROSIS; GENE EXPRESSION; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY; SKIN; SMOOTH MUSCLE;

ACTINS; ANTIBODIES, ANTI-IDIOTYPIC; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; CELLS, CULTURED; CHEMOKINE CCL2; COCULTURE TECHNIQUES; COLLAGEN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROBLASTS; FIBROSIS; GENE EXPRESSION; HUMANS; IMMUNOGLOBULIN M; INTERLEUKIN-6; MATRIX METALLOPROTEINASE 9; MUSCLE, SMOOTH; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SCLERODERMA, SYSTEMIC; SKIN; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84886213424     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4352     Document Type: Article

References (36)

1. Mouthon L. SSc in 2011: from mechanisms to medicines. Nat Rev Rheumatol 2012, 8:72-74.
2. Romano E, Manetti M, Guiducci S, Ceccarelli C, Allanore Y, Matucci-Cerinic M. The genetics of systemic sclerosis: an update. Clin Exp Rheumatol 2011, 29:S75-S86.
3. LeRoy EC, Medsger TA. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001, 28:1573-1576.
4. Novobrantseva TI, Majeau GR, Amatucci A, Kogan S, Brenner I, Casola S, Shlomchik MJ, Koteliansky V, Hochman PS, Ibraghimov A. Attenuated liver fibrosis in the absence of B cells. J Clin Invest 2005, 115:3072-3082. 10.1172/JCI24798, 1265860, 16276416.
5. Komura K, Yanaba K, Horikawa M, Ogawa F, Fujimoto M, Tedder TF, Sato S. CD19 regulates the development of bleomycin-induced pulmonary fibrosis in a mouse model. Arthritis Rheum 2008, 58:3574-3584. 10.1002/art.23995, 18975313.
6. Kraaij MD, van Laar JM. The role of B cells in systemic sclerosis. Biologics 2008, 2:389-395. 2721390, 19707370.
7. Whitfield ML, Finlay DR, Murray JI, Troyanskaya OG, Chi JT, Pergamenschikov A, McCalmont TH, Brown PO, Botstein D, Connolly MK. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci USA 2003, 100:12319-12324. 10.1073/pnas.1635114100, 218756, 14530402.
8. Duncan MR, Berman B. Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6. J Invest Dermatol 1991, 97:686-692.
9. Sato S, Hasegawa M, Takehara K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 2001, 27:140-146. 10.1016/S0923-1811(01)00128-1, 11532378.
10. Saito F, Tasaka S, Inoue K, Miyamoto K, Nakano Y, Ogawa Y, Yamada W, Shiraishi Y, Hasegawa N, Fujishima S, Takano H, Ishizaka A. Role of interleukin-6 in bleomycin-induced lung inflammatory changes in mice. Am J Respir Cell Mol Biol 2008, 38:566-571. 10.1165/rcmb.2007-0299OC, 18096870.
11. Verrecchia F, Laboureau J, Verola O, Roos N, Porcher R, Bruneval P, Ertault M, Tiev K, Michel L, Mauviel A, Farge D. Skin involvement in scleroderma: where histological and clinical scores meet. Rheumatology (Oxford) 2007, 46:833-841. 10.1093/rheumatology/kel451, 17255134.
12. Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol 2009, 9:491-502. 10.1038/nri2572, 19521398.
13. Kalled SL. The role of BAFF in immune function and implications for autoimmunity. Immunol Rev 2005, 204:43-54. 10.1111/j.0105-2896.2005.00219.x, 15790349.
14. Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, Tschopp J, Browning JL. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999, 190:1697-1710. 10.1084/jem.190.11.1697, 2195729, 10587360.
15. Matsushita T, Fujimoto M, Hasegawa M, Tanaka C, Kumada S, Ogawa F, Takehara K, Sato S. Elevated serum APRIL levels in patients with systemic sclerosis: distinct profiles of systemic sclerosis categorized by APRIL and BAFF. J Rheumatol 2007, 34:2056-2062.
16. Matsushita T, Hasegawa M, Yanaba K, Kodera M, Takehara K, Sato S. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 2006, 54:192-201. 10.1002/art.21526, 16385515.
17. Ng LG, Sutherland AP, Newton R, Qian F, Cachero TG, Scott ML, Thompson JS, Wheway J, Chtanova T, Groom J, Sutton IJ, Xin C, Tangye SG, Kalled SL, Mackay F, Mackay CR. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol 2004, 173:807-817.
18. Kim WU, Min SY, Cho ML, Hong KH, Shin YJ, Park SH, Cho CS. Elevated matrix metalloproteinase-9 in patients with systemic sclerosis. Arthritis Res Ther 2005, 7:R71-R79. 10.1186/ar1454, 1064883, 15642145.
19. Henault J, Robitaille G, Senecal JL, Raymond Y. DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I autoantibodies from systemic sclerosis patients. Arthritis Rheum 2006, 54:963-973. 10.1002/art.21646, 16508979.
20. Sato S, Fujimoto M, Hasegawa M, Takehara K, Tedder TF. Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis. Mol Immunol 2004, 41:1123-1133. 10.1016/j.molimm.2004.06.025, 15482848.
21. Sato S, Hasegawa M, Fujimoto M, Tedder TF, Takehara K. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 2000, 165:6635-6643.
22. Sato S, Fujimoto M, Hasegawa M, Takehara K. Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum 2004, 50:1918-1927. 10.1002/art.20274, 15188368.
23. Chizzolini C, Parel Y, De Luca C, Tyndall A, Akesson A, Scheja A, Dayer JM. Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor alpha. Arthritis Rheum 2003, 48:2593-2604. 10.1002/art.11129, 13130479.
24. Chizzolini C, Rezzonico R, Ribbens C, Burger D, Wollheim FA, Dayer JM. Inhibition of type I collagen production by dermal fibroblasts upon contact with activated T cells: different sensitivity to inhibition between systemic sclerosis and control fibroblasts. Arthritis Rheum 1998, 41:2039-2047. 10.1002/1529-0131(199811)41:11<2039::AID-ART20>3.0.CO;2-1, 9811060.
25. Kondo K, Okada T, Matsui T, Kato S, Date K, Yoshihara M, Nagata Y, Takagi H, Yoneda M, Sugie I. Establishment and characterization of a human B cell line from the lung tissue of a patient with scleroderma; extraordinary high level of IL-6 secretion by stimulated fibroblasts. Cytokine 2001, 13:220-226. 10.1006/cyto.2000.0822, 11237429.
26. Abraham DJ, Krieg T, Distler J, Distler O. Overview of pathogenesis of systemic sclerosis. Rheumatology (Oxford) 2009, 48:iii3-iii7. 10.1093/rheumatology/ken481, 19487220.
27. Young-Min SA, Beeton C, Laughton R, Plumpton T, Bartram S, Murphy G, Black C, Cawston TE. Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls. Ann Rheum Dis 2001, 60:846-851. 1753839, 11502611.
28. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007, 117:557-567. 10.1172/JCI31139, 1804347, 17332883.
29. Kirk TZ, Mark ME, Chua CC, Chua BH, Mayes MD. Myofibroblasts from scleroderma skin synthesize elevated levels of collagen and tissue inhibitor of metalloproteinase (TIMP-1) with two forms of TIMP-1. J Biol Chem 1995, 270:3423-3428. 10.1074/jbc.270.7.3423, 7852429.
30. Yoshimoto K, Tanaka M, Kojima M, Setoyama Y, Kameda H, Suzuki K, Tsuzaka K, Ogawa Y, Tsubota K, Abe T, Takeuchi T. Regulatory mechanisms for the production of BAFF and IL-6 are impaired in monocytes of patients of primary Sjogren's syndrome. Arthritis Res Ther 2011, 13:R170. 10.1186/ar3493, 3308105, 22018243.
31. Couture P, Paradis-Massie J, Oualha N, Thibault G. Adhesion and transcellular migration of neutrophils and B lymphocytes on fibroblasts. Exp Cell Res 2009, 315:2192-2206. 10.1016/j.yexcr.2009.04.013, 19394331.
32. Bosello S, De Santis M, Lama G, Spano C, Angelucci C, Tolusso B, Sica G, Ferraccioli G. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther 2010, 12:R54. 10.1186/ar2965, 2888203, 20338043.
33. Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Korfiatis P, Yiannopoulos G, Andonopoulos AP. Is there a role for B-cell depletion as therapy for scleroderma? A case report and review of the literature. Semin Arthritis Rheum 2010, 40:127-136. 10.1016/j.semarthrit.2009.09.003, 20004954.
34. Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Paliogianni F, Sirinian C, Yiannopoulos G, Andonopoulos AP. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol 2011, 30:S17-S22.
35. Hasegawa M, Hamaguchi Y, Yanaba K, Bouaziz JD, Uchida J, Fujimoto M, Matsushita T, Matsushita Y, Horikawa M, Komura K, Takehara K, Sato S, Tedder TF. B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol 2006, 169:954-966. 10.2353/ajpath.2006.060205, 1698806, 16936269.
36. Matsushita T, Fujimoto M, Hasegawa M, Matsushita Y, Komura K, Ogawa F, Watanabe R, Takehara K, Sato S. BAFF antagonist attenuates the development of skin fibrosis in tight-skin mice. J Invest Dermatol 2007, 127:2772-2780.